GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Product-specific reference

Micafungin (Mycamine)

Read renal action and limits
Local official-label summarySource retrieved 2026-09-05See the evidence for this drug6 sources available - open source summaries, references and comparisons

Mycamine

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (6)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Mycamine - product and source limitations

The appropriate daily dose depends on infection and treatment intent.

Before applying: Verify the current prescribing information for this presentation.

Also check: Mycamine - product and source limitations

Rxlist source

Mycamine - selected RX renal passage

Choose a product and source Product label UCSF Infectious Diseases Management Program All evidence
Product / population
Micafungin (Mycamine), adult IV infusion
Renal measure
Use the renal measure explicitly present in the RX passage.
Source revision
Mirror revision not established in the reviewed passage.
Retrieved
2026-11-07 (not the revision date)

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

This mirror and the underlying product label share a source family.

RX List: selected renal passage

The mirror describes similar exposure in a small severe-impairment study and no renal dose change.

Source revision: Mirror revision not established in the reviewed passage. | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/mycamine-drug/

Scope: Selected renal passages reviewed; independent clinician adjudication pending. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

Mycamine - labeled renal guidance

Source retrieved 2026-11-07 - confirm current applicability

Qualified no-adjustment instruction; review dialysis evidence limits

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Mycamine - labeled renal guidance

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Dialysis evidence: Qualified no-adjustment instruction; review dialysis evidence limits

Micafungin (Mycamine), adult IV infusion

Renal method: Clinical renal category or population named in the cited section
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
GlobalRPh RX List

Mycamine - selected RX renal passage

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Micafungin (Mycamine), adult IV infusion

Renal method: Use the renal measure explicitly present in the RX passage.
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
Professional guidance

Mycamine - UCSF Infectious Diseases Management Program

Professional guidance with defined scope. Publication date, institutional setting and source limitations remain controlling. This is not automatic preference over another source.

UCSF adult IV micafungin for candidemia/invasive candidiasis.

Renal method: Adult HD and nondialysis tables, indication-specific.
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
Handbook

Renal Drug Handbook, 5th edition - Micafungin

Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.

Renal method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.
Retrieved: 2026-09-05

Read local renal resultOpen this source quick answer

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Mycamine - product and source limitations

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Handbook source

Renal Drug Handbook, 5th edition - Micafungin

Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.

Method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.

Historical renal / replacement-therapy guidanceRead this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeMYCAMINE - adult indication-specific dosingMycamine - labeled renal guidanceMycamine - selected RX renal passageUCSF - micafungin by infectionMycamine - UCSF Infectious Diseases Management ProgramRenal Drug Handbook, 5th edition - Micafungin
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a064c4a7-25ec-4a2c-afc2-703491a4a38b

Product and population scope

Adult Micafungin (Mycamine). Use only the product, route, indication and renal-replacement setting explicitly stated in the source protocol selected below. Sources are alternatives to compare, not ingredients of a blended regimen.

SCOPE-micafungin · Source section: Editorial scope; each clinical recommendation is separately attributed belowRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

MYCAMINE - adult indication-specific dosing

Open original reference

Open / share this exact local source

NIH/NLM DailyMed - U.S. product labeling · Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.

Renal method: No renal-function dose bands specified for this summary.
Source date: Selected label updated 2020-07-23; this older selected label is not a claim of latest manufacturer-wide revision.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Adult indicationIV dose once daily
Candidemia, disseminated Candida infection, Candida peritonitis or abscess100 mg
Esophageal candidiasis150 mg
Candida prophylaxis during hematopoietic stem-cell transplantation50 mg

Infuse over 1 hour. Renal impairment does not require adjustment, and no supplemental dose is required after hemodialysis. Monitor renal and hepatic tests despite the absence of a dose reduction. The label has not adequately studied Candida endocarditis, osteomyelitis or meningoencephalitis; the institutional high-dose protocols are separate recommendations.

RDM30-076-micafungin-1 · Source locator: MYCAMINE - adult indication-specific dosing; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a064c4a7-25ec-4a2c-afc2-703491a4a38b
Retrieved
2026-09-05
DailyMed Set ID
a064c4a7-25ec-4a2c-afc2-703491a4a38b
Renal-function method
No renal-function dose bands specified for this summary.
Source date/version
Selected label updated 2020-07-23; this older selected label is not a claim of latest manufacturer-wide revision.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
9771c73bff75fa6c14ebf740650f9aff32dc7420fa800c6a13c2089b4d154344
Official

Mycamine - labeled renal guidance

Open original reference

Open / share this exact local source

FDA / product prescribing information · Micafungin (Mycamine), adult IV infusion

Renal method: Clinical renal category or population named in the cited section
Source date: Prescribing information revised 8/2016
Retrieved: 2026-11-07

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Dialysis evidence: Qualified no-adjustment instruction; review dialysis evidence limits

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 8.6 and 12.3

Use the indication-specific dose across renal impairment. A supplementary dose after hemodialysis is unnecessary. The appropriate daily dose depends on infection and treatment intent.

RDM73-mycamine-official-1 · Source locator: Renal guidance: 8.6 and 12.3

Source identity and provenance
Source family
product_label
Source
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021506s019lbl.pdf
Retrieved
2026-11-07
Renal-function method
Clinical renal category or population named in the cited section
Source date/version
Prescribing information revised 8/2016
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
5bd2a48a8d36bf314be0ecf8c7a40502e0275bca27b446561aa7efc0c7985988
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Mycamine - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Micafungin (Mycamine), adult IV infusion

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

The mirror describes similar exposure in a small severe-impairment study and no renal dose change.

RDM73-mycamine-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/mycamine-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
8472594b98d046adea5360f54f099c1c5aad725d06fac54f64121351d74dfaad
Separate handbook layer

Renal Drug Handbook cross-check

Handbook

Renal Drug Handbook, 5th edition - Micafungin

Open / share this exact local source

UK Renal Pharmacy Group / CRC Press · Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.

Renal method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.
Source date: 5th edition; 2019 copyright; historical reference
Retrieved: 2026-09-05

Historical handbook cross-check; not a current U.S. protocol

Historical renal / replacement-therapy guidance

The 20-50, 10-20 and <10 mL/min bands retain the usual indication-specific dose. PD, HD, high-flux and continuous therapy also retain usual doses; the book describes no dialysis removal. Its broad dose range is indication- and weight-dependent, so use the separate U.S. adult indication doses. The book notes reports of renal dysfunction/AKI despite the no-adjustment recommendation.

HB30-micafungin-1 · Source locator: Printed page 655: renal impairment, RRT and other information

Source-specific limits

Separate source recommendation, not proof of agreement or contemporary clinical validation. Dialysis predictions are retained with their original certainty.

Source identity and provenance
Retrieved
2026-09-05
Handbook page
5th edition, printed p. 655; uploaded PDF p. 674
Renal-function method
Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.
Source date/version
5th edition; 2019 copyright; historical reference
U.S. product identity basis
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a064c4a7-25ec-4a2c-afc2-703491a4a38b
Hash meaning
Local paraphrase; original book not redistributed
Local summary SHA-256
c8e813f2ec9efa47c74c6d5dfa63e9a818c720c5478c1e99e1fa0184e8da8ddb
Separate professional-source layer

University and professional protocols

Professional

UCSF - micafungin by infection

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: Qualitative no-adjustment recommendation.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

For candidemia, invasive candidiasis and the listed ICU/neutropenic empiric-treatment settings, the adult regimen is 100 mg IV daily. Esophageal candidiasis, endocarditis and cardiac-device infection use 150 mg daily. Candida prevention in selected transplant, neutropenic or hematologic-malignancy patients uses 50-100 mg daily.

UCSF retains these doses in renal dysfunction and its dialysis table. Obesity, elevated MICs and some deep infections may require specialist-directed higher doses. This institutional indication list is broader than some labeled uses.

RDM30-035-micafungin-1 · Source locator: UCSF - micafungin by infection; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/micafungin
Retrieved
2026-09-05
Renal-function method
Qualitative no-adjustment recommendation.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
b2e51aa16001c4ccae896476df17b08db7555d45f385ffe17e0c20a0df772f83
Professional

Mycamine - UCSF Infectious Diseases Management Program

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · UCSF adult IV micafungin for candidemia/invasive candidiasis.

Renal method: Adult HD and nondialysis tables, indication-specific.
Source date: Online guidance checked 2026-11-07; section revision not established.
Retrieved: 2026-11-07

Professional guidance with defined scope. Publication date, institutional setting and source limitations remain controlling. This is not automatic preference over another source.

Selected renal passages reviewed; independent clinician adjudication pending.

Adult nondialysis and dialysis, candidemia

For candidemia or invasive candidiasis, UCSF lists 100 mg IV every 24 hours both off dialysis and in its HD tables. Other infections and prophylaxis use different doses. For deep infection, elevated MIC or obesity, consult the antimicrobial stewardship service.

RDM73-mycamine-professional-1 · Source locator: Adult nondialysis and dialysis, candidemia

Source identity and provenance
Source family
professional_guideline
Source
https://idmp.ucsf.edu/content/micafungin
Retrieved
2026-11-07
Renal-function method
Adult HD and nondialysis tables, indication-specific.
Source date/version
Online guidance checked 2026-11-07; section revision not established.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
682647dd6afb4d7d11821f802fab7ccca7ec7f095d6b8d13f4b26e7ac5066ed5

Provenance and preservation

Additional summaries stored on this page: 2 official-label, 1 RX List, 2 professional, 1 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a064c4a7-25ec-4a2c-afc2-703491a4a38b
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
6c6464fa31c4d57c684265bebb54762af8f8567a085de78442858b02df03d00e
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report
Top